Achieve Life Sciences Will Appoint New CFO in October
Seattle-based Achieve Life Sciences will transition financial leadership as it prepares for the potential commercialization of its lead product.
Updated on Oct. 1, 2026 in Corporate Finance
Live Poll
Do you trust that new leadership better positions pharmaceutical companies to successfully deliver medical treatments?
Effective October 5, 2026, Benjamin Halladay will succeed Mark Oki as Chief Financial Officer of Achieve Life Sciences. Halladay joins the Seattle-based company as it moves toward the potential commercial launch of its smoking cessation drug, cytisinicline.
Why it matters
The appointment signals a strategic pivot for Achieve as it shifts from clinical development to commercial readiness. Operators in the biotech sector should note how leadership changes often correlate with the transition from regulatory submission to go-to-market execution.
Halladay brings 15 years of experience to the role, following a tenure at Esperion Therapeutics that included managing $400 million in annual revenue. The move comes as Achieve prepares to address a market segment where 25 million U.S. adults smoke combustible cigarettes.
The players
Achieve Life Sciences
A Seattle-based biopharmaceutical company focused on the development of cytisinicline to aid in smoking cessation.
Benjamin Halladay
A Certified Public Accountant with 15 years of financial management experience who previously served as CFO at Esperion Therapeutics.
Mark Oki
The outgoing CFO who led the company's financial strategy through its Phase 3 program and NDA submission.
Esperion Therapeutics
A pharmaceutical company where Halladay previously managed $400 million in annual revenue prior to its $1.1 billion sale.
The details
Halladay will assume oversight of financial strategy, accounting, investor relations, and information technology. He takes the reins from Mark Oki, who managed the company's financial operations through the Phase 3 clinical program and the subsequent New Drug Application submission. The transition is designed to bolster the firm’s executive capabilities as it plans for the commercialization of its primary candidate, cytisinicline.
Timeline
October 5, 2026: Halladay assumes CFO role and Oki steps down.
Market Landscape
The transition follows the pattern of biotech firms hiring executives with recent experience in corporate M&A and large-scale revenue management. This follows the $1.1 billion acquisition of Esperion Therapeutics by ARCHIMED, which set a benchmark for the scale of operations Halladay managed.
Operators in the pharmaceutical space should monitor this transition as a potential indicator of an imminent commercial launch strategy. Finance leaders should evaluate whether their internal accounting and investor relations infrastructure is scaled to handle the shift from clinical to commercial operation.
The takeaway
Leadership changes at the CFO level often serve as a bellwether for a firm's transition from R&D to market entry. Monitor the company's investor relations updates after October 5, 2026, for guidance on their commercialization timeline and anticipated capital requirements.
Further reading
For more on industry leadership trends, visit /finance/corporate-finance/.
Live Poll
Do you trust that new leadership better positions pharmaceutical companies to successfully deliver medical treatments?
